Developer docs
API playgroundTry for free, no card

Search company profiles

BIOMILQ

Full company profile

uuid0000dzs

Namestring
BIOMILQ
Legal namestring
BIOMILQ, INC.,
Websiteurl
biomilq.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

BIOMILQ is a women-owned and science-led start-up building a mammary biomanufacturing platform to produce bioauthentic human milk ingredients for better human health. By combining the unique capabilities of human mammary cells with a scalable biomanufacturing process, BIOMILQ aims to demonstrate the power of our platform through impact in early-life nutrition with ingredients that promote immune, gut, and neurological development.

Short descriptiontext

Unlocking human potential with breakthrough mammary biotechnology.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersDurham, United States
HQ citystring
Durham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell-cultured breastmilk, infant nutrition biotechnology, mammary cell cultivation, cultured dairy alternatives, cellular agriculture nutrition
NAICS code1 code
  • Dairy Product (except Frozen) Manufacturing31151
SIC code1 code
  • Dairy Products2020
Product category
Cell-Cultured Infant Milk
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Human mammary cell-derived milk product
TypeOne Time License
Description

BIOMILQ is developing a human mammary cell-derived milk product as an infant feeding alternative, targeting the infant formula market with a breastmilk-like product that has a lower environmental footprint.

prnewswire.com
Cost components4 values
Technology or R&D, Personnel, Operations, Infrastructure
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

BIOMILQ is developing a cell-cultured human milk product using human mammary cells to replicate the milk production conditions found inside the human body. The product is intended to serve as a breastmilk-like infant feeding alternative with a lower environmental footprint than conventional infant formula. The company is currently in the development and regulatory navigation phase and has not yet launched a commercial product.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Lower environmental footprint compared to conventional infant formula
Product overview1 text field

BIOMILQ is a biotechnology company developing a single core product: cell-cultured human milk derived from human mammary cells. The company replicates milk production conditions found inside the human body to create a breastmilk-like infant feeding alternative. The company is currently in development stage with no commercial product launched yet, working toward market entry within approximately four years while navigating regulatory pathways.

Product and service1 record
1Cell-Cultured Human Milk
CategoryCell-Cultured Infant Milk
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BIOMILQ

Cell-Cultured Infant Milkbiomilq.com

Unlocking human potential with breakthrough mammary biotechnology.

What BIOMILQ does

BIOMILQ is a women-owned and science-led start-up building a mammary biomanufacturing platform to produce bioauthentic human milk ingredients for better human health. By combining the unique capabilities of human mammary cells with a scalable biomanufacturing process, BIOMILQ aims to demonstrate the power of our platform through impact in early-life nutrition with ingredients that promote immune, gut, and neurological development.

BIOMILQ firmographics

Firmographics
Name
BIOMILQ
Legal name
BIOMILQ, INC.,
Website
https://biomilq.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Short description
Unlocking human potential with breakthrough mammary biotechnology.
Ownership category
akta.pro rank

Where BIOMILQ is headquartered

Location

Headquarters

HQ city
Durham
HQ country
United States
HQ region
North America

Offices1 record

Markets served

BIOMILQ business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure

Revenue model

  1. Human mammary cell-derived milk product: BIOMILQ is developing a human mammary cell-derived milk product as an infant feeding alternative, targeting the infant formula market with a breastmilk-like product that has a lower environmental footprint.

Go-to-market motion1 record

BIOMILQ product offering

Product offering

Core offering

BIOMILQ is developing a cell-cultured human milk product using human mammary cells to replicate the milk production conditions found inside the human body. The product is intended to serve as a breastmilk-like infant feeding alternative with a lower environmental footprint than conventional infant formula. The company is currently in the development and regulatory navigation phase and has not yet launched a commercial product.

Product overview

BIOMILQ is a biotechnology company developing a single core product: cell-cultured human milk derived from human mammary cells. The company replicates milk production conditions found inside the human body to create a breastmilk-like infant feeding alternative. The company is currently in development stage with no commercial product launched yet, working toward market entry within approximately four years while navigating regulatory pathways.

Differentiator

Problem solved

Functional benefit

Products and services

  • Cell-Cultured Human Milk

Quantifiable outcome

  • Lower environmental footprint compared to conventional infant formula

Companies that use BIOMILQ

Customer profile

Segments1 record

Ideal customer profiles1 record

BIOMILQ technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

BIOMILQ partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

BIOMILQ competitors and assessment

Company assessment

Market position

Weaknesses5 records

Competitive moat5 records

Customer concentration

BIOMILQ social profiles

Digital presence

BIOMILQ financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BIOMILQ leadership team

Management profile

Number of profiles

Profiles2 records

BIOMILQ funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BIOMILQ M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BIOMILQ

What does BIOMILQ do?

BIOMILQ is developing a cell-cultured human milk product using human mammary cells to replicate the milk production conditions found inside the human body. The product is intended to serve as a breastmilk-like infant feeding alternative with a lower environmental footprint than conventional infant formula. The company is currently in the development and regulatory navigation phase and has not yet launched a commercial product.

Is BIOMILQ a public or private company?

BIOMILQ is a private company. It is classified as venture growth investor backed and is currently operating.

When was BIOMILQ founded?

BIOMILQ was founded in 2020. It employs 1 to 10 people.

Where is BIOMILQ based?

BIOMILQ is headquartered in Durham, United States, in the North America region.

How does BIOMILQ make money?

One revenue line is on record: human mammary cell-derived milk product.

Does BIOMILQ have an API?

No public API is recorded for BIOMILQ.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business InsiderWhy Are so Many Young People Getting Colon Cancer? the Answer Could Trace Back to InfancyResearchers are investigating why early-onset colorectal cancer is rising among young, healthy adults, with new evidence suggesting DNA damage may begin in infancy due to specific bacterial toxins and microbiome disruptions. Studies indicate that factors such as C-section births, formula feeding, and high-sugar diets contribute to these early microbial shifts, prompting the development of targeted infant probiotics and modified formulas by companies like Biomilq and Helaina. The findings highlight a complex interplay between early-life environmental exposures and long-term cancer risk, moving beyond traditional adult lifestyle factors.NatureLab-grown breast milkMultiple biotech startups are developing lab-grown breast milk components, including Helaina, Checkerspot, and Biomilq, which have raised tens of millions in funding. The global cell-based milk market was valued at $450 million in 2023 and is expected to grow at 8.8% annually through 2029. Companies aim to produce HMOs, lactoferrin, and fats to bridge the gap between formula and breast milk.NatureBiomanufacturing human milk components to improve early-life nutritionBIOMILQ produces human milk components from human mammary epithelial cells, aiming to bridge infant formula and breast milk. The company is developing bio-authentic human osteopontin, which differs from bovine versions, and plans to commercialize products within a year.PR NewswireWomen-owned Startups Collaborate Toward a Scalable and Cost-Effective Future for Sustainable BiotechnologyTiamat Sciences and BIOMILQ have collaborated to demonstrate that Tiamat's plant-based recombinant Human Prolactin is as effective as commercial alternatives while being ten times more affordable. This partnership aims to reduce production costs for cell-based food and life sciences industries by providing scalable, animal-free protein inputs.WsjWSJ’s The Future of EverythingThree startups—Helaina, BIOMILQ, and Wilk—are developing products that mimic components of human breast milk, such as lactoferrin and cell-cultured milk. They have raised tens of millions in funding and plan to launch adult nutrition products first, with infant products expected by 2030. The FDA has not yet established regulations for these products.WRAL TechWireBill Gates-backed lab-grown breast milk startup’s new CEO braces for challengesBIOMILQ, a Durham biotech startup backed by Bill Gates's Breakthrough Energy Ventures, raised $3.5 million in seed funding in early 2020 to produce lab-grown breast milk. CEO Leila Strickland, who took over from Michelle Egger, says the company is prioritizing hard science over a fast market entry and faces regulatory hurdles with the FDA. The company plans another funding round next year.CNBCLab-grown breast milk startup Biomilq aims to change infant nutrition — if it can release a productBiomilq, a North Carolina-based startup, is developing lab-grown breast milk to address supply chain vulnerabilities in the infant formula industry and provide an alternative nutrition source. The company faces significant regulatory hurdles from the FDA, potential consumer skepticism, and internal leadership changes as it navigates a tightening venture capital environment for biotech firms. A prototype product is estimated to be three to five years away from market release.The New YorkerBiomilq and the New Science of Artificial Breast MilkBiomilq, a biotech startup, is developing lab-grown breast milk from human mammary cells. The company has produced lactose and casein, and raised $21 million in 2021. It aims to make the product affordable and accessible, though it cannot yet replicate breast milk's full composition.NyerBiomilq and the New Science of Artificial Breast MilkBiomilq, a North Carolina startup, uses lab-cultured human mammary cells to produce milk components, including lactose and casein. The company raised $3.5 million in 2020 and $21 million in 2021, but its product lacks antibodies and variability of breast milk. Founders aim for accessibility but expect initial pricing above infant formula.The WireGetting Lab-Grown Meat – And Milk – To the Table – The Wire ScienceUpside Foods received US regulatory approval for its cultured chicken, marking a significant step toward commercializing cellular agriculture despite remaining technical and cost hurdles. Other companies like Good Meat, Opalia, and BioMilq are developing similar cell-based meat and milk products, with some already available in Singapore or in development for human breast milk. The industry faces challenges in scaling production to reduce costs and optimize nutrient media before these alternatives can compete broadly with conventional animal products.